# MiMedx Group Inc (MDXG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $4.57, market value $667 million.

## Valuation
- **P/E (trailing): 114.3×** (5-yr avg 26.4×, 3-yr avg 26.4×). MiMedx Group Inc trades at 114.3× trailing earnings, well above its own five-year average of 26.4×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.60**. A PEG of 1.60 is in the range usually read as fairly priced for its growth.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 45.1×**. Enterprise value is 45.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Earnings yield: 0.9%**. The inverse of the P/E: 0.9% of the price is earned each year.

## Profitability
- **Gross margin: 78.8%**. MiMedx Group Inc keeps 78.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 2.5%**. 2.5% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 11.6%**. 11.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.9%**. 18.9% on shareholders' equity is solid.
- **Return on invested capital: 6.4%**. Return on all capital, debt included, is 6.4%.
- **Return on assets: 1.8%**. Each dollar of assets produces 1.8% of profit.

## Growth
- **Revenue growth (1 yr): 20.0%** (3-yr 16.1%/yr, 5-yr 11.0%/yr). Revenue grew 20.0% over the last year, against 11.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 14.3%**. Earnings per share rose 14.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.07**. Debt is 0.07 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. MiMedx Group Inc holds more cash than debt.
- **Altman Z-score: 7.53**. A Z-score of 7.53 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. MiMedx Group Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover MiMedx Group Inc; the consensus is strong_buy, with an average price target of $7.40 (+62% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -35.5%** (YTD -32.5%, 3-mo 22.2%). The shares are down 35.5% over twelve months including dividends.
- **From 52-week high: -42.7%** (50.8% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 1.02** (volatility 41%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MDXG · Page: https://foliofundamentals.com/stocks/mdxg

Not investment advice.